Expanded Access of Pimavanserin for Patients With PD Psychosis
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this program is to provide patients with PDP access to pimavanserin until the
product receives marketing approval from the FDA and is commercially available.